Bristol Myers Squibb Therapy Delayed Tumor Growth
The RYZ101 treatment showed success in patients with advanced gastrointestinal and pancreatic tumors.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that major pharmaceutical companies are effectively developing life-saving cancer treatments?
Bristol Myers Squibb reported that its RYZ101 therapy successfully delayed disease progression in patients with advanced gastrointestinal and pancreatic tumors. The company shares increased nearly 4% in pre-market trading following the news of the late-stage trial results.
Why it matters
The successful trial represents a key development for the therapy acquired by the company through a multi-billion dollar takeover. It offers a potential new path for patients who have seen their disease progress after undergoing Lutetium-177-based treatments.
The RYZ101 therapy utilizes the radioactive isotope actinium-225 to deliver radiation directly to tumor cells. The drug's safety profile remained consistent with results observed in previous studies.
The players
Bristol Myers Squibb
This global biopharmaceutical company focuses on discovering and developing innovative medicines for serious diseases.
RayzeBio
This biotechnology company specializes in radiopharmaceutical therapeutics and was acquired by Bristol Myers Squibb.
The details
The late-stage trial evaluated the efficacy of RYZ101 against standard-of-care treatments for gastroenteropancreatic neuroendocrine tumors. By delivering radioactive particles directly to tumor-associated cells, the therapy aims to provide a targeted intervention for complex oncology cases.
Timeline
Bristol Myers reported the late-stage trial results on October 12, 2026.
The Big Picture
This development in targeted radiopharmaceuticals, specifically the RYZ101 therapy, signals a shift toward more precise radiation delivery in oncology. It marks a departure from broader, less-targeted systemic treatments by using isotope-based precision to address treatment-resistant tumors.
Patients who have exhausted options following Lutetium-177-based therapies may find a new clinical pathway through this treatment. As the company moves to discuss data with regulators, the focus remains on the drug's safety profile relative to existing standards of care.
The takeaway
This trial progress highlights the potential of radioactive isotopes to treat advanced tumors that have resisted other therapies. Patients and their care teams should continue monitoring clinical trial updates as the company pursues regulatory discussions.
What happens next
Bristol Myers plans to present detailed study results at a future medical meeting and is actively pursuing earlier-stage trials for hormone receptor-positive metastatic breast cancer.
Further reading
For more on the latest research in this field, visit the Cancer section.
Live Poll
Do you trust that major pharmaceutical companies are effectively developing life-saving cancer treatments?
